FATE | Fate Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.85 - 4.17
52 Week Range	1.6300 - 8.83
Beta	2.13
Implied Volatility	114.62%
IV Rank	-2.49%
Day's Volume	1,216,752
Average Volume	1,866,075
Shares Outstanding	113,878,000
Market Cap	450,956,880
Sector	Healthcare
Industry	Biotechnology
IPO Date	2013-10-01

Valuation
Profitability
Growth
Health
P/E Ratio	-2.33
Forward P/E Ratio	-3.41
EPS	-1.70
1YR Price Target	46.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	181
Country	USA
Website	FATE

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

FATE's peers: ADMA, ALLK, ARCT, ATRA, BEAM, CGC, CRBU, CRSP, EVGN, SANA, RCUS, NTLA, EDIT, VERV, THRX, LIFE, RLAY, IPSC, BPMC, PRME, GTHX, MCRB, TXG, PLUR

*Chart delayed

Analyzing fundamentals for FATE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see FATE Fundamentals page.

Watching at FATE technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on FATE Technicals page.